The new plans are in addition to $21B that the drug manufacturer has already committed to U.S. research, development and ...

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump ...

Gilead Sciences announced $11 billion in new planned investment in the U.S. to boost its domestic manufacturing and research ...

Gilead Sciences announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research ...

After six chilling seasons, The Handmaid’s Tale is coming to an end, with star Yvonne Strahovski promising a powerful conclusion.

Businesses that are solid enough to perform well over extended periods, while consistently raising their payouts, are precisely what income investors should gravitate toward. Here are two corporations ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

Gilead Sciences said Wednesday it will invest $11 billion in U.S. research and manufacturing in the coming years, joining ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

The show’s bleak and uncompromising final chapter is yet another gripping demonstration of how fear metastasises into fascism ...